key: cord-0955786-l6ycww2q
authors: Butt, Adeel A.; Dargham, Soha R.; Loka, Srusvin; Shaik, Riyazuddin M.; Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter V.; Yassine, Hadi M.; Al-Khatib, Hebah A.; Smatti, Maria K.; Kaleeckal, Anvar H.; Latif, Ali Nizar; Zaqout, Ahmed; Almaslamani, Muna A.; Al Khal, Abdullatif; Bertollini, Roberto; Abou-Samra, Abdul-Badi; Abu-Raddad, Laith J.
title: COVID-19 Disease Severity in Children Infected with the Omicron Variant
date: 2022-04-11
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac275
sha: 369c12b2813b0232c444e6899584f1a7b3327451
doc_id: 955786
cord_uid: l6ycww2q

BACKGROUND: There are limited data assessing COVID-19 disease severity in children/adolescents infected with the Omicron variant. METHODS: We identified children and adolescents <18 years with SARS-CoV-2 infection with Delta and propensity-score matched controls with Omicron variant infection from the National COVID-19 Database in Qatar. Primary outcome was disease severity, determined by hospital admission, admission to ICU, or mechanical ventilation within 14 days of diagnosis, or death within 28 days. RESULTS: Among 1,735 cases with Delta variant infection between June 1 and November 6, 2021 and 32 635 cases with Omicron variant infection between January 1 and January 15, 2022 who did not have prior infection and were not vaccinated, we identified 985 propensity-score matched pairs. Among Delta infected, 84.2% had mild, 15.7% had moderate, and 0.1% had severe/critical disease. Among Omicron infected, 97.8% had mild, 2.2% had moderate, and none had severe/critical disease (P < .001). Omicron variant infection (vs. Delta) was associated with significantly lower odds of moderate or severe/critical disease (adjusted odds ratio, 0.12; 95% CI 0.07-0.18). Those aged 6–11, and 12-<18 years had lower odds of developing moderate or severe/critical disease compared with those younger than six years (aOR, 95% CI 0.47; 0.33-0.66 for 6-11 year old; aOR 0.45, 95% CI 0.21-0.94 for 12-<18 years old). CONCLUSIONS: Omicron variant infection in children/adolescents is associated with less severe disease than Delta variant infection as measured by hospitalization rates and need for ICU care or mechanical ventilation. Those 6 to <18 years also have less severe disease than those <6 years old.

The study was conducted in Qatar, which has high rates of testing and vaccination of the 3 eligible population for SARS-CoV-2.

[16] Since the identification of the first patient with SARS-4

CoV-2 on February 27, 2020, Qatar has experienced four distinct waves, now attributed to the 5 wild-type, Alpha, Beta, and Omicron variants. [17] [18] [19] [20] [21] [22] It also experienced a prolonged low-6 incidence phase with the Delta variant. [17] [18] [19] [20] [21] [22] The first case of Omicron variant infection in 7

Qatar was identified in a traveler on November 24, 2021, and within 4 weeks, it became the 8 predominant circulating variant. [22] Starting very early in the pandemic, Qatar also instituted an 9 aggressive testing policy, which included testing of all persons with compatible symptoms, 10 contacts of confirmed cases, returning travelers, and persons in frontline high-risk professions 11 (e.g. healthcare workers and school staff) and screening of certain high-risk groups. Real-time 12 reverse-transcription PCR (RT-qPCR) was used to test for SARS-CoV-2 on nasopharyngeal 13 swabs at two national laboratories at Hamad Medical Corporation and Sidra Medicine. 14

Using the national COVID-19 database in Qatar, which includes every PCR test performed in 16

Qatar since the beginning of the pandemic, [23] [24] [25] we identified children (0-<18 years) with 17

Delta variant infection diagnosed between June 1 and November 6, 2021, and those with 18

Omicron variant infection diagnosed between January 1 and January 15, 2022. We excluded 19 those with prior documented infection and those who had received any SARS-CoV-2 20 vaccination. Among these, we propensity-score matched each Delta infection case with an 21

Omicron infection case based on age, gender, nationality, and presence of comorbidities. We 22 performed 1:1 matching, using the nearest neighbor matching with a caliper of 0.2SD. 23

The primary outcome of interest was severity of COVID-19 disease in children and adolescents 2 infected with the Delta variant compared with those infected with the Omicron variant. Disease 3 severity was categorized into mild (RT-PCR confirmed infection not requiring hospitalization), 4 moderate (requiring acute care hospitalization but no intensive care unit admission or 5 mechanical ventilation or death), and severe/critical (admission to an intensive care unit, 6 mechanical ventilation, or death). All outcomes within 14 days of the index positive test were 7 included, except death for which a 28-day period was included. All children with COVID-19 in 8

Qatar requiring hospitalization are admitted to designated public hospitals, thereby ensuring 9 complete capture of all hospital admissions and subsequent inpatient care. Comorbidities were 10 identified based on associated diagnostic codes in the electronic medical records, as used in 11 our previous publications.[26-28] SARS-CoV-2 infection was confirmed from the national 12 COVID-19 database. [23] [24] [25] Vaccination status was also confirmed from the national COVID-19 13 database, which contains a record of every SARS-CoV-2 vaccinated person in Qatar. [23, 24] 14

Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in 16

Universal Transport Medium (UTM). Aliquots of UTM were: 1) extracted on a KingFisher Flex 17 Omicron coincided with the intense Omicron wave where Delta incidence was very limited. 5

Accordingly, any PCR-positive test between January 1 and 15, 2022 was used as a proxy for 6

Omicron infection. 7

In our recent analysis of the adult population in Qatar, we found that 15.2% of those infected We calculated and compared the proportions of persons with mild, moderate, or severe/critical 19 disease among those infected with the Delta and the Omicron variants. 95% confidence 20 intervals (CIs) were calculated to express the spread. Multivariable logistic regression was used 21

to calculate the adjusted odds ratios (aORs) and 95% CIs for factors associated with these 22

outcomes. Where p-values were used for comparison, a p-value<0.05 was considered 23 Review Boards approved this study. A waiver of informed consent was granted due to the 5 retrospective nature of data retrieval. were included in the final analysis. (Figure 1 ) Among those with Delta variant infection, the 10 median age was 7 years (IQR 3-9), 54.6% were females, 39.5% were Qataris and 85.7% had 11 no comorbidities. Among those with Omicron variant infection, the median age was 6 years 12 (IQR 3-10), 52.2% were females, 36.8% were Qataris and 85.6% had no comorbidities. (Table  13 1) Individual comorbidities and the baseline characteristics of the entire study population before 14 propensity score matching ( and comorbidity count were not associated with the odds of developing moderate or 2 severe/critical disease. (Table 3) 3

We also conducted logistic regression analysis by disease severity stratified by the infecting 4 variant. (Table 4 ) For both Delta and Omicron variant infection, those aged 6-11 years had 5 lower odds of developing moderate or severe/critical disease compared with those younger than For those with Omicron variant infection, the presence of one or more comorbidity was 8 associated with higher odds of developing moderate or severe/critical disease (aOR 3.16, 95% 9 CI 1.11-9.00). This association was not significant among those with Delta variant infection. 10 (Table 4 ) 11

In this large national study, we describe the severity of COVID-19 disease in children infected it is intuitive to assume that children and adolescents with inherently lesser comorbidities would 1 experience significantly less severe disease outcomes. It is possible that the threshold for 2 admission was lower in children and adolescents, which is the definition of moderate disease. 3

However, criteria for mechanical ventilation are not likely to be much different, with such 4 interventions executed only in those with severe or critical disease. 5

Within children and adolescents, those who were 6-11 years old were less likely to have 6 moderate or severe/critical disease compared with those younger than 6 years old. Whether this 7 is due to a poorer immune response or other reasons such as the anatomy of the upper 8 respiratory tract in small children is not clear. As mentioned earlier, another possibility is the 9 lower threshold for admitting younger patients compared with older individuals with the same 10 severity of symptoms. If the safety and efficacy of the current vaccines are confirmed in children 11 younger than 6 years old, these data provide supporting evidence to extend the vaccination to 12 this age group. 13

We noted that the presence of comorbidities was associated with moderate or severe outcomes Strengths of our study include a large national population, extensive testing, and uniform data 1 collection methods. All children and adolescents requiring inpatient care were admitted to 2 designated facilities, providing a high degree of uniformity in admission criteria and subsequent 3 care, including decisions to transfer to an intensive care setting and initiation of mechanical 4 ventilation. Certain limitations also need to be noted. This was a retrospective study, and 5 despite propensity-score matching, the possibility of residual confounding cannot be excluded. 6

While the study excluded persons with a documented prior infection, some of the prior infections 7 may have not been documented. With Omicron cases being diagnosed several weeks after 8 Delta cases, it is possible that some of the observed lower severity of Omicron infections could 9 be due to a higher level of accrued natural immunity. However, this may only explain a small 10 part of the lower severity of Omicron infections as the infection diagnosis rate is high in the 11 pediatric population in Qatar as a consequence of the high testing rates. 12

In conclusion, infection with the Omicron variant in children and adolescents is associated with 13 significantly lower severity of infection as measured by hospitalization rates and need for 14 intensive care unit care or mechanical ventilation. This is reassuring considering the large 15 number of children and adolescents infected during the Omicron wave across the globe. 

Severity of 2 Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar

Hospital 5 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared 6 with alpha (B.1.1.7) variants of concern: a cohort study

The reproductive number of the Delta variant of SARS-CoV-2 is far 8 higher compared to the ancestral SARS-CoV-2 virus

Rapid Increase 11 in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -Mesa County

Clinical and virological 14 features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 15 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)

SARS-CoV-2 Omicron variant 18 shows less efficient replication and fusion activity when compared with Delta variant in 19 TMPRSS2-expressed cells

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in 22

Early assessment 1 of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A

Systematic Review

Multisystem Inflammatory Syndrome in Children -Initial Therapy and Outcomes

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

Hospitalizations of 21 Children and Adolescents with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Ministry of Public Health Qatar COVID-19 Vaccination Program Data

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar

Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the 10 Variants of Concern in Qatar

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Effectiveness 18 of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and 22 severe COVID-19 disease in Qatar

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

National Project of Surveillance for Variants of Concern and Viral Genome 13

Qatar viral genome sequencing data. Data on randomly collected samples

COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in

Tracking SARS-CoV-2 variants

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar